Latest & greatest articles for myocardial infarction

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on myocardial infarction or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on myocardial infarction and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for myocardial infarction

41. Oxygen Therapy in Patients with Acute Myocardial Infarction: A Systemic Review and Meta-Analysis

Oxygen Therapy in Patients with Acute Myocardial Infarction: A Systemic Review and Meta-Analysis 29355510 2018 03 08 1555-7162 2018 Mar 05 The American journal of medicine Am. J. Med. Oxygen Therapy in Patients with Acute Myocardial Infarction: A Systemic Review and Meta-Analysis. S0002-9343(18)30017-2 10.1016/j.amjmed.2017.12.027 Oxygen therapy is frequently used for patients with acute myocardial infarction. The aim of this study is to perform a systematic review and meta-analysis to compare (...) the outcomes of oxygen therapy versus no oxygen therapy in post-acute myocardial infarction settings. A systematic search of electronic databases was conducted for randomized studies, which reported cardiovascular events in oxygen versus no oxygen therapy. The evaluated outcomes were all-cause mortality, recurrent coronary events (ischemia or myocardial infarction), heart failure, and arrhythmias. Summary-adjusted risk ratios (RRs) were calculated by the random effects DerSimonian and Laird model. The risk

EvidenceUpdates2018

42. Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study.

Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study. OBJECTIVE: To compare the risk of in-hospital mortality associated with haloperidol compared with atypical antipsychotics in patients admitted to hospital with acute myocardial infarction. DESIGN: Cohort study using a healthcare database. SETTING: Nationwide sample of patient data from more than 700 hospitals across the United States. PARTICIPANTS: 6578 (...) medical patients aged more than 18 years who initiated oral haloperidol or oral atypical antipsychotics (olanzapine, quetiapine, risperidone) during a hospital admission with a primary diagnosis of acute myocardial infarction between 2003 and 2014. MAIN OUTCOME MEASURE: In-hospital mortality during seven days of follow-up from treatment initiation. RESULTS: Among 6578 patients (mean age 75.2 years) treated with an oral antipsychotic drug, 1668 (25.4%) initiated haloperidol and 4910 (74.6%) initiated

BMJ2018 Full Text: Link to full Text with Trip Pro

43. Inhibitory mechanisms of very low–dose rivaroxaban in non–ST-elevation myocardial infarction

Inhibitory mechanisms of very low–dose rivaroxaban in non–ST-elevation myocardial infarction 29588304 2018 11 14 2473-9537 2 6 2018 03 27 Blood advances Blood Adv Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction. 715-730 10.1182/bloodadvances.2017013573 Very low-dose (VLD) factor Xa (FXa) inhibition, in combination with acetylsalicylic acid (ASA) and clopidogrel, is associated with improved outcomes in patients with acute coronary syndrome (ACS (...) ) with a tolerable bleeding risk profile. To date, there are no data documenting platelet inhibition and the anticoagulatory effects of VLD FXa inhibition on top of guideline-adherent dual-antiplatelet therapy (DAPT) in patients with ACS. Patients with non-ST-elevation myocardial infarction (NSTEMI) receiving oral DAPT (ASA + clopidogrel, n = 20; or ASA + ticagrelor, n = 20) were prospectively enrolled in a nonrandomized study. Coagulation- and platelet-dependent thrombin generation (TG), measured by means

Blood advances2018 Full Text: Link to full Text with Trip Pro

44. Long-term impact of chronic total occlusion recanalisation in patients with ST-elevation myocardial infarction

Long-term impact of chronic total occlusion recanalisation in patients with ST-elevation myocardial infarction 29463612 2018 02 21 1468-201X 2018 Feb 20 Heart (British Cardiac Society) Heart Long-term impact of chronic total occlusion recanalisation in patients with ST-elevation myocardial infarction. heartjnl-2017-312698 10.1136/heartjnl-2017-312698 During primary percutaneous coronary intervention (PCI), a concurrent chronic total occlusion (CTO) is found in 10% of patients with ST-elevation (...) myocardial infarction (STEMI). Long-term benefits of CTO-PCI have been suggested; however, randomised data are lacking. Our aim was to determine mid-term and long-term clinical outcome of CTO-PCI versus CTO-No PCI in patients with STEMI with a concurrent CTO. The Evaluating Xience and left ventricular function in PCI on occlusiOns afteR STEMI (EXPLORE) was a multicentre randomised trial that included 302 patients with STEMI after successful primary PCI with a concurrent CTO. Patients were randomised to either CTO

EvidenceUpdates2018

45. Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation

Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation 29447733 2018 02 15 1558-3597 71 7 2018 Feb 20 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Stroke Risk in Patients With Reduced Ejection Fraction After Myocardial Infarction Without Atrial Fibrillation. 727-735 S0735-1097(17)41924-3 10.1016/j.jacc.2017.12.011 Stroke can occur after myocardial infarction (MI) in the absence of atrial fibrillation (AF). This study (...) sought to identify risk factors (excluding AF) for the occurrence of stroke and to develop a calibrated and validated stroke risk score in patients with MI and heart failure (HF) and/or systolic dysfunction. The datasets included in this pooling initiative were derived from 4 trials: CAPRICORN (Effect of Carvedilol on Outcome After Myocardial Infarction in Patients With Left Ventricular Dysfunction), OPTIMAAL (Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan), VALIANT

EvidenceUpdates2018

46. Effect of a Quality Improvement Intervention on Clinical Outcomes in Patients in India With Acute Myocardial Infarction: The ACS QUIK Randomized Clinical Trial.

Effect of a Quality Improvement Intervention on Clinical Outcomes in Patients in India With Acute Myocardial Infarction: The ACS QUIK Randomized Clinical Trial. Importance: Wide heterogeneity exists in acute myocardial infarction treatment and outcomes in India. Objective: To evaluate the effect of a locally adapted quality improvement tool kit on clinical outcomes and process measures in Kerala, a southern Indian state. Design, Setting, and Participants: Cluster randomized, stepped-wedge (...) clinical trial conducted between November 10, 2014, and November 9, 2016, in 63 hospitals in Kerala, India, with a last date of follow-up of December 31, 2016. During 5 predefined steps over the study period, hospitals were randomly selected to move in a 1-way crossover from the control group to the intervention group. Consecutively presenting patients with acute myocardial infarction were offered participation. Interventions: Hospitals provided either usual care (control group; n = 10 066 participants

JAMA2018 Full Text: Link to full Text with Trip Pro

47. Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock

Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock Acute heart failure following myocardial infarction: complement activation correlates with the severity of heart failure in patients developing cardiogenic shock Hilde L. Orrem 1 , Per H. Nilsson 1,2,3 , Søren E. Pischke 1,4 , Guro Grindheim 4 , Peter Garred 5 , Ingebjørg Selje?ot 6,7,10 ,Trygve Husebye 7,10,11 , Pål Aukrust 2,8,9,10 (...) of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; 11 Center of Heart Failure Research, University of Oslo, Oslo, Norway; 12 Research Laboratory Nordland Hospital, Bodø and K.G. Jebsen TREC, University of Tromsø,Tromsø, Norway; 13 Centre of Molecular In?ammation Research, Norwegian University of Science and Technology,Trondheim, Norway Abstract Aims Heart failure (HF) is an impending complication to myocardial infarction. We hypothesized that the degree of comple- ment activation

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

48. Meta-Analysis of Culprit-Only Versus Multivessel Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Disease

Meta-Analysis of Culprit-Only Versus Multivessel Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Disease 29304995 2018 02 08 1879-1913 121 5 2018 Mar 01 The American journal of cardiology Am. J. Cardiol. Meta-Analysis of Culprit-Only Versus Multivessel Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Disease. 529-536 S0002-9149(17)31847-7 10.1016 (...) /j.amjcard.2017.11.022 Recently, several randomized controlled trials (RCT) in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease (MVD) have compared a strategy of routine multivessel percutaneous coronary intervention (PCI) performed either as a single procedure or as staged procedures to culprit-only PCI. All of these trials have been underpowered for clinical end points. We searched PubMed, Embase, and Cochrane Central Register of Controlled Trials for RCT

EvidenceUpdates2018

49. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection.

Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. BACKGROUND: Acute myocardial infarction can be triggered by acute respiratory infections. Previous studies have suggested an association between influenza and acute myocardial infarction, but those studies used nonspecific measures of influenza infection or study designs that were susceptible to bias. We evaluated the association between laboratory-confirmed influenza infection and acute myocardial infarction. METHODS (...) : We used the self-controlled case-series design to evaluate the association between laboratory-confirmed influenza infection and hospitalization for acute myocardial infarction. We used various high-specificity laboratory methods to confirm influenza infection in respiratory specimens, and we ascertained hospitalization for acute myocardial infarction from administrative data. We defined the "risk interval" as the first 7 days after respiratory specimen collection and the "control interval" as 1

NEJM2018

50. The impact of a dose of the angiotensin receptor blocker valsartan on post‐myocardial infarction ventricular remodelling

The impact of a dose of the angiotensin receptor blocker valsartan on post‐myocardial infarction ventricular remodelling The impact of a dose of the angiotensin receptor blocker valsartan on post‐myocardial infarction ventricular remodelling - Park - 2018 - ESC Heart Failure - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search term Search Search term Search The full text of this article hosted at iucr.org is unavailable due (...) to technical difficulties. Original Research Article Open Access The impact of a dose of the angiotensin receptor blocker valsartan on post‐myocardial infarction ventricular remodelling Division of Cardiology, Department of Internal Medicine, Dong‐A University Hospital, Busan, Republic of Korea Corresponding Author E-mail address: Division of Cardiology, Department of Internal Medicine, Dong‐A University Hospital, Busan, Republic of Korea Correspondence to: Young‐Dae Kim, Regional Cardiovascular Center

ESC heart failure2018 Full Text: Link to full Text with Trip Pro

51. Staff Recall Travel Time for ST Elevation Myocardial Infarction Impacted by Traffic Congestion and Distance: A Digitally Integrated Map Software Study

Staff Recall Travel Time for ST Elevation Myocardial Infarction Impacted by Traffic Congestion and Distance: A Digitally Integrated Map Software Study January 2018 | Volume 4 | Article 89 1 Original r esearch published: 08 January 2018 doi: 10.3389/fcvm.2017.00089 Frontiers in Cardiovascular Medicine | www.frontiersin.org Edited by: Takatoshi Kasai, Juntendo University, Japan Reviewed by: Ryo Naito, Juntendo University, Japan Nazareno Paolocci, Johns Hopkins University, United States (...) *Correspondence: Jamie Layland jlayland@phcn.vic.gov.au † First author. Specialty section: This article was submitted to General Cardiovascular Medicine, a section of the journal Frontiers in Cardiovascular Medicine Received: 12 October 2017 Accepted: 15 December 2017 Published: 08 January 2018 Citation: Cole J, Beare R, Phan TG, Srikanth V, MacIsaac A, Tan C, Tong D, Yee S, Ho J and Layland J (2018) Staff Recall Travel Time for ST Elevation Myocardial Infarction Impacted by Traffic Congestion and Distance

Frontiers in cardiovascular medicine2018 Full Text: Link to full Text with Trip Pro

52. Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: A population-based cohort study

Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: A population-based cohort study 29171906 2017 12 28 1463-1326 2017 Nov 24 Diabetes, obesity & metabolism Diabetes Obes Metab Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: A population-based cohort study. 10.1111/dom.13168 We investigated the association between the current use of individual sulphonylureas and the risk of a first-ever (...) acute myocardial infarction (AMI) and all-cause mortality, in a population-based cohort study, using primary care data from the Clinical Practice Research Datalink database (2004-2012). New users (N = 121 869), aged ≥18 years, with at least one prescription for a non-insulin antidiabetic agent were included. The first prescription defined start of follow-up. Time-dependent Cox proportional hazard models were used to estimate the risk of a first-ever AMI and all-cause mortality associated

EvidenceUpdates2018 Full Text: Link to full Text with Trip Pro

53. Non-ST-elevation myocardial infarction

Non-ST-elevation myocardial infarction Non-ST-elevation myocardial infarction - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Non-ST-elevation myocardial infarction Last reviewed: August 2018 Last updated: March 2018 Summary Part of the acute coronary syndrome spectrum. Usually caused by a partial or near-complete occlusion of a coronary artery resulting in compromised blood flow to myocardium with subsequent (...) myocardial injury. Patients typically present with chest pressure/discomfort lasting at least several minutes, at times accompanied by sweating, dyspnoea, nausea, and/or anxiety. Symptoms are indistinguishable from those of unstable angina. However, non-ST-elevation MI is differentiated from unstable angina by a rise of cardiac biomarkers. ECG is the first-line investigation in all patients and should not be delayed for history, examination, or other tests. Early risk stratification and treatment

BMJ Best Practice2018

54. ST-elevation myocardial infarction

ST-elevation myocardial infarction ST-elevation myocardial infarction - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  ST-elevation myocardial infarction Last reviewed: August 2018 Last updated: May 2018 Summary Presents with central chest pain that is classically heavy in nature, like a sensation of pressure or squeezing. Examination is variable, and findings range from normal to a critically unwell patient (...) in cardiogenic shock. ST-elevation MI (STEMI) is suspected when a patient presents with persistent ST-segment elevation in 2 or more anatomically contiguous ECG leads in the context of a consistent clinical history. CK-MB and cardiac-specific troponins confirm diagnosis. Treatment should, however, be started immediately in patients with a typical history and ECG changes, without waiting for laboratory results. Immediate and prompt revascularisation can prevent or decrease myocardial damage and decrease

BMJ Best Practice2018

55. Impact of a ‘stent for life’ initiative on post‐ST elevation myocardial infarction heart failure: a 15 year heart failure clinic experience

Impact of a ‘stent for life’ initiative on post‐ST elevation myocardial infarction heart failure: a 15 year heart failure clinic experience Impact of a ‘stent for life’ initiative on post-ST elevation myocardial infarction heart failure: a 15 year heart failure clinic experience Antoni Bayes-Genis 1,2,3 * , Cosme García 1,2,3 , Marta de Antonio 1,3 , Eduard Fernandez-Nofrerías 1 , Mar Domingo 1 , Elisabet Zamora 1,2,3 , Pedro Moliner 1 and Josep Lupón 1,2,3 1 Heart Institute, Hospital (...) Universitari Germans Trias i Pujol, Badalona, Spain; 2 Department de Medicina, Universitat Autònoma de Medicina, Barcelona, Spain; 3 CIBERCV (CB16/11/00403), Instituto de Salud Carlos III, Madrid, Spain Abstract Aims Multidisciplinary heart failure (HF) clinics are a cornerstone of contemporary HF management. The stent-for-life (SFL) initiative improves mortality after ST elevation myocardial infarction (STEMI), but its impact in post-STEMI HF is not well characterized. Here we assessed the impact of SFL

ESC heart failure2017 Full Text: Link to full Text with Trip Pro

56. Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study

Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study 29122893 2017 11 10 1935-5548 2017 Nov 09 Diabetes care Diabetes Care Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study. dc170476 10.2337/dc17-0476 The cardiovascular safety of saxagliptin, a dipeptidyl-peptidase 4 inhibitor, compared with other antihyperglycemic treatments is not well understood. We (...) prospectively examined the association between saxagliptin use and acute myocardial infarction (AMI). We identified patients aged ≥18 years, starting from the approval date of saxagliptin in 2009 and continuing through August 2014, using data from 18 Mini-Sentinel data partners. We conducted seven sequential assessments comparing saxagliptin separately with sitagliptin, pioglitazone, second-generation sulfonylureas, and long-acting insulin, using disease risk score (DRS) stratification and propensity score

EvidenceUpdates2017

57. Blood Transfusion in Elderly Patients with Acute Myocardial Infarction: Data from the RICO Survey

Blood Transfusion in Elderly Patients with Acute Myocardial Infarction: Data from the RICO Survey 29030059 2017 12 19 1555-7162 2017 Oct 10 The American journal of medicine Am. J. Med. Blood Transfusion in Elderly Patients with Acute Myocardial Infarction: Data from the RICO Survey. S0002-9343(17)31013-6 10.1016/j.amjmed.2017.09.027 Red blood cell transfusion benefit during acute myocardial infarction remains unclear in the elderly. We aimed to assess the transfusion impact on 1-year mortality (...) in acute myocardial infarction patients aged ≥65 years, according to their age and hemoglobin nadir. We included 3316 consecutive patients with acute myocardial infarction aged ≥65 years from the "obseRvatoire des Infarctus de Côte d'Or" (RICO) survey. They were categorized according to their hemoglobin nadir (≤8, >8 to ≤10, and >10 g/dL) and age (<80 or ≥80 years). A total of 1906 patients (57%) were 65-79 years old, and 1410 (43%) were aged ≥80 years, of whom 103 (5%) and 145 (10%) patients received

EvidenceUpdates2017

58. MiRroring the Multiple Potentials of MicroRNAs in Acute Myocardial Infarction

MiRroring the Multiple Potentials of MicroRNAs in Acute Myocardial Infarction November 2017 | Volume 4 | Article 73 1 Review published: 20 November 2017 doi: 10.3389/fcvm.2017.00073 Frontiers in Cardiovascular Medicine | www.frontiersin.org Edited by: Junjie Xiao, Shanghai University, China Reviewed by: Nazareno Paolocci, Johns Hopkins University, United States Valdo Jose Dias Da Silva, Universidade Federal do Triângulo Mineiro, Brazil *Correspondence: Onnik Agbulut onnik.agbulut@upmc.fr (...) Specialty section: This article was submitted to General Cardiovascular Medicine, a section of the journal Frontiers in Cardiovascular Medicine Received: 12 August 2017 Accepted: 31 October 2017 Published: 20 November 2017 Citation: Paiva S and Agbulut O (2017) MiRroring the Multiple Potentials of MicroRNAs in Acute Myocardial Infarction. Front. Cardiovasc. Med. 4:73. doi: 10.3389/fcvm.2017.00073 MiRroring the Multiple Potentials of MicroRNAs in Acute Myocardial infarction Solenne Paiva and Onnik

Frontiers in cardiovascular medicine2017 Full Text: Link to full Text with Trip Pro

59. Patient selection for high sensitivity cardiac troponin testing and diagnosis of myocardial infarction: prospective cohort study.

Patient selection for high sensitivity cardiac troponin testing and diagnosis of myocardial infarction: prospective cohort study. Objective To evaluate how selection of patients for high sensitivity cardiac troponin testing affects the diagnosis of myocardial infarction across different healthcare settings. Design Prospective study of three independent consecutive patient populations presenting to emergency departments. Setting Secondary and tertiary care hospitals in the United Kingdom (...) and United States. Participants High sensitivity cardiac troponin I concentrations were measured in 8500 consecutive patients presenting to emergency departments: unselected patients in the UK (n=1054) and two selected populations of patients in whom troponin testing was requested by the attending clinician in the UK (n=5815) and the US (n=1631). The final diagnosis of type 1 or type 2 myocardial infarction or myocardial injury was independently adjudicated. Main outcome measures Positive predictive

BMJ2017 Full Text: Link to full Text with Trip Pro

60. Direct Comparison of Cardiac Myosin-Binding Protein C With Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction

Direct Comparison of Cardiac Myosin-Binding Protein C With Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction 28972002 2017 10 03 2017 10 24 2017 10 24 1524-4539 136 16 2017 Oct 17 Circulation Circulation Direct Comparison of Cardiac Myosin-Binding Protein C With Cardiac Troponins for the Early Diagnosis of Acute Myocardial Infarction. 1495-1508 10.1161/CIRCULATIONAHA.117.028084 Cardiac myosin-binding protein C (cMyC) is a cardiac-restricted protein that is more abundant (...) than cardiac troponins (cTn) and is released more rapidly after acute myocardial infarction (AMI). We evaluated cMyC as an adjunct or alternative to cTn in the early diagnosis of AMI. Unselected patients (N=1954) presenting to the emergency department with symptoms suggestive of AMI, concentrations of cMyC, and high-sensitivity (hs) and standard-sensitivity cTn were measured at presentation. The final diagnosis of AMI was independently adjudicated using all available clinical and biochemical

EvidenceUpdates2017 Full Text: Link to full Text with Trip Pro